News
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...
GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...
These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...
While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...
Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...
Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results